Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CollPlant BiotechnologiesFRA:CPT 48 Equity-to-Asset is 0.53 as of Mar. 2026, which is 22% below its 10-year median of 0.68. GuruFocus rates FRA:CPT with a GF Score™ of 48/100 and a GF Value™ of €2.89 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,415 Biotechnology companies, CollPlant Biotechnologies ranks worse than 64.59% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
CollPlant Biotechnologies Equity-to-Asset Related Terms
CollPlant Biotechnologies Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CPT vs DRMA, AAGH, HCWB: Equity-to-Asset Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
CollPlant Biotechnologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies (FRA:CPT) has a Equity-to-Asset of 0.53 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CollPlant Biotechnologies and its competitors. This is 22% below median its historical median of 0.68. According to the industry distribution chart, CollPlant Biotechnologies ranks #914 out of 1415 companies in the Biotechnology industry, placing it in the top 64.6%.
Is CollPlant Biotechnologies' Equity-to-Asset too high?
CollPlant Biotechnologies' current Equity-to-Asset of 0.53 is 22% below median its 10-year median of 0.68. The Biotechnology industry median Equity-to-Asset is 0.68. CollPlant Biotechnologies' value of 0.53 is 22.1% below this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #914 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CollPlant Biotechnologies has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Equity-to-Asset compare to DRMA and AAGH?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #914 out of 1415 companies for Equity-to-Asset. This places CollPlant Biotechnologies in the lower half of its industry. The industry median Equity-to-Asset is 0.68. CollPlant Biotechnologies' value of 0.53 is 22.1% below this benchmark. While the company's 10-year median is 0.68 vs. the industry median of 0.68, CollPlant Biotechnologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current Equity-to-Asset of 0.53 is 22.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current Equity-to-Asset is 0.53, which is 22% below median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.89, compared to a current price of €3.50 — trading 21.1% above its estimated fair value. The current Equity-to-Asset is 0.53, which is 22% below median its 10-year median of 0.68 and 22.1% below the Biotechnology industry median of 0.68. CollPlant Biotechnologies' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current Equity-to-Asset is 0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €3.50 is trading 21.1% above its estimated GF Value™ of €2.89.
GuruFocus considers CollPlant Biotechnologies to be Significantly Overvalued.
Key valuation signals for FRA:CPT:
Equity-to-Asset: 0.53 (22% below median its 10-year median of 0.68)
GF Value™: €2.89 vs. price of €3.50 (21.1% above fair value)
Industry Position: 22.1% below the Biotechnology median (#914 of 1415)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
48GF Score
Get the complete analysis for FRA:CPT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 
